Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of HealthEquity, Inc. (NASDAQ:HQY). In a filing disclosed on September 04th, the Representative disclosed that they had bought between $1,001 and $15,000 in HealthEquity stock on July 10th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Purchased $15,001 - $50,000 in shares of Mesabi Trust NYSE: MSB on 7/31/2026.
- Purchased $1,001 - $15,000 in shares of Praxis Precision Medicines NASDAQ: PRAX on 7/30/2026.
- Purchased $15,001 - $50,000 in shares of Alkermes NASDAQ: ALKS on 7/30/2026.
- Sold $15,001 - $50,000 in shares of Crinetics Pharmaceuticals NASDAQ: CRNX on 7/30/2026.
- Sold $100,001 - $250,000 in shares of Alibaba Group NYSE: BABA on 7/24/2026.
- Sold $1,001 - $15,000 in shares of Adobe NASDAQ: ADBE on 7/24/2026.
- Sold $1,001 - $15,000 in shares of Viavi Solutions NASDAQ: VIAV on 7/21/2026.
- Purchased $1,001 - $15,000 in shares of SailPoint NASDAQ: SAIL on 7/21/2026.
- Purchased $1,001 - $15,000 in shares of Glacier Bancorp NYSE: GBCI on 7/21/2026.
- Sold $1,001 - $15,000 in shares of FedEx NYSE: FDX on 7/21/2026.
HealthEquity Stock Performance
Shares of HQY opened at $96.07 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.99 and a current ratio of 2.99. The company has a market cap of $7.95 billion, a price-to-earnings ratio of 34.68, a PEG ratio of 1.52 and a beta of 0.22. The stock has a fifty day moving average price of $99.53 and a two-hundred day moving average price of $88.86. HealthEquity, Inc. has a 52-week low of $72.76 and a 52-week high of $107.62.
HealthEquity (NASDAQ:HQY - Get Free Report) last announced its earnings results on Thursday, August 27th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.19 by $0.05. HealthEquity had a return on equity of 15.33% and a net margin of 17.36%.The company had revenue of $350.73 million for the quarter, compared to analysts' expectations of $349.22 million. The company's revenue was up 95.5% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. Analysts predict that HealthEquity, Inc. will post 3.93 EPS for the current fiscal year.
Institutional Investors Weigh In On HealthEquity
A number of institutional investors and hedge funds have recently modified their holdings of HQY. Corient Private Wealth LP grew its holdings in HealthEquity by 8.6% during the 2nd quarter. Corient Private Wealth LP now owns 29,789 shares of the company's stock worth $2,691,000 after acquiring an additional 2,364 shares during the period. Amundi grew its stake in shares of HealthEquity by 33.6% during the second quarter. Amundi now owns 90,327 shares of the company's stock worth $8,158,000 after purchasing an additional 22,735 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in HealthEquity in the second quarter valued at about $2,619,000. California State Teachers Retirement System increased its holdings in HealthEquity by 8,679.7% in the second quarter. California State Teachers Retirement System now owns 8,832,754 shares of the company's stock valued at $797,774,000 after purchasing an additional 8,732,150 shares during the last quarter. Finally, HB Wealth Management LLC lifted its stake in HealthEquity by 70.2% in the second quarter. HB Wealth Management LLC now owns 4,671 shares of the company's stock valued at $422,000 after buying an additional 1,927 shares during the period. 99.55% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of brokerages have commented on HQY. Deutsche Bank Aktiengesellschaft increased their price objective on shares of HealthEquity from $135.00 to $142.00 and gave the stock a "buy" rating in a report on Monday, August 31st. Citigroup reiterated a "market outperform" rating on shares of HealthEquity in a research report on Friday, August 28th. Barrington Research reissued an "outperform" rating and set a $110.00 price target on shares of HealthEquity in a research note on Friday, May 22nd. Citizens Jmp raised their price target on shares of HealthEquity from $110.00 to $111.00 and gave the company a "market outperform" rating in a report on Monday, June 1st. Finally, Weiss Ratings restated a "hold (c+)" rating on shares of HealthEquity in a research report on Wednesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, HealthEquity currently has a consensus rating of "Moderate Buy" and a consensus target price of $111.87.
View Our Latest Stock Report on HQY
Insider Activity
In related news, EVP Michael Fiore sold 2,470 shares of HealthEquity stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $95.00, for a total transaction of $234,650.00. Following the transaction, the executive vice president owned 56,643 shares of the company's stock, valued at $5,381,085. This trade represents a 4.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Adrian T. Dillon sold 7,632 shares of the business's stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $104.61, for a total transaction of $798,383.52. Following the transaction, the director owned 62,395 shares of the company's stock, valued at approximately $6,527,140.95. This represents a 10.90% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 12,456 shares of company stock valued at $1,256,664 over the last 90 days. Corporate insiders own 1.60% of the company's stock.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About HealthEquity
(
Get Free Report)
HealthEquity, Inc NASDAQ: HQY is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.
Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.